Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
70.3% downsideOvervalued by 70.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.65 Billion |
|---|---|
| Enterprise Value | $4.33 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $6.44 |
| Beta | 1.07 |
| Outstanding Shares | 19,883,000 |
Return
| Return on Equity | 14.12% |
|---|---|
| Return on Assets | 9.19% |
| Return on Invested Capital | 11.08% |
Valuation & Multiples
| P/E Ratio | 30.03 |
|---|---|
| PEG | -43.81 |
| Price to Sales | 18.15 |
| Price to Book Ratio | 4.72 |
| Enterprise Value to Revenue | 15.77 |
| Enterprise Value to EBIT | 26.19 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8262▲ 64.87% |
|---|---|
| Total Calls | 42,000▲ 18.31% |
| Total Puts | 34,700▲ 450.79% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.43%▼ 0.65% |
|---|---|
| Total Invested | $4.15B▲ 6.86% |
| Investors Holding | 362▲ 9.00% |
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid pricing, which are critical determinants of revenue and profitability for pharmaceutical companies like Ligand Pharmaceuticals. Members would possess non-public information on these market-moving policies.
This committee directly regulates the FDA (drug approval is existential for pharma companies) and the NIH (key for research funding), profoundly impacting the primary operations and financial success of Ligand Pharmaceuticals.
This committee oversees intellectual property (patent) law and antitrust, which are foundational to the pharmaceutical industry's business model (especially for a company like Ligand Pharmaceuticals that relies on licensing technologies) and M&A activity.